Assisted Reproductive Therapy Safe in Women With IBD, but Efficacy Mixed Assisted Reproductive Therapy Safe in Women With IBD, but Efficacy Mixed
Assisted reproductive therapy is safe in women with inflammatory bowel disease, with outcomes likely similar in women with ulcerative colitis and medically managed Crohn ' s disease compared with the general population, suggest results of a systematic review and meta-analysis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 10, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab Colitis Study: Ozanimod Tops Adalimumab, Equals Vedolizumab
In a statistical comparison, ozanimod matched vedolizumab and beat adalimumab for ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - November 2, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Upadacitinib Shows Potential for Ulcerative Colitis Upadacitinib Shows Potential for Ulcerative Colitis
Good efficacy and safety data provide hope for upadacitinib as an alternative JAK inhibitor for ulcerative colitis.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 26, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
New Analyses Suggest Favorable Results for STELARA ® (ustekinumab) When Used as a First-Line Therapy for Bio-Naïve Patients with Moderately to Severely Active Crohn’s Disease and Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 25, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from two new analyses of STELARA® (ustekinumab) for the treatment of adults with moderately to severely active Crohn’s disease (CD) and ulcerative colitis (UC).1,2 In a modelled analysisa focused on treatment sequencing using data from randomized controlled trials, network meta-analysis and literature, results showed patient time spent in clinical remission or response was highest when STELARA was used as a first-line advanced therapy for bio-naïve patients with moderately to severely acti...
Source: Johnson and Johnson - October 25, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Ustekinumab Maintenance Therapy in Ulcerative Colitis Ustekinumab Maintenance Therapy in Ulcerative Colitis
This study to assess the real-world effectiveness and safety of ustekinumab in patients with refractory ulcerative colitis confirms long-term effectiveness with a good safety profile.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 20, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Rectal Compliance Lower Than Normal in Ulcerative Colitis, but Recovery Is Possible Rectal Compliance Lower Than Normal in Ulcerative Colitis, but Recovery Is Possible
Rectal compliance is lower in patients with ulcerative colitis than in those without, but recovery is possible, researchers suggest.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 8, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
Janssen Submits Application Seeking U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Pediatric Patients With Juvenile Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, October 8, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking expanded approval of STELARA® (ustekinumab) to treat pediatric patients ages 5 years and older with juvenile psoriatic arthritis (jPsA).The filing is supported by extrapolation of data from nine studies across both adult trials in active PsA and adult and pediatric studies in moderate to severe plaque psoriasis, totaling 3,997 patients evaluated across these closely associated dis...
Source: Johnson and Johnson - October 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
How to Maintain Your Social Life When You Have IBD
About two years ago, as Samantha Plevney was dealing with a major Crohn’s disease flare-up, she decided to tell her gastroenterologist how it was affecting her emotional health.
“I told him that I’m alive but I’m not living,” she recalls. “Not being able to see my friends because of the uncertainty of my health situation was making me feel worse. I think people with IBD, and their doctors, tend to focus on physical symptoms, and for good reason. But the mental-health effect that comes from social support is huge.”
Inflammatory bowel disease (IBD) encompasses two conditions—Cr...
Source: TIME: Health - October 5, 2021 Category: Consumer Health News Authors: Elizabeth Millard Tags: Uncategorized Source Type: news
New Analysis Presented by Janssen at United European Gastroenterology Week (UEGW) Demonstrates Long-Term Safety Profile for STELARA ® (ustekinumab) in Older Patients Across Approved Indications
SPRING HOUSE, PENNSYLVANIA, October 4, 2021 – Today, the Janssen Pharmaceutical Companies of Johnson & Johnson announced a new analysis of STELARA® (ustekinumab) pooled safety data from 13 clinical studies across approved indications, showing rates of key safety events among adults 60 years and older treated with STELARA for up to five yearsa were similar to rates observed with placebo during the control phase of these trials.1,b Approved indications included adults with moderately to severely active Crohn’s disease (CD), moderately to severely active ulcerative colitis (UC), moderate to severe plaque psoriasis (P...
Source: Johnson and Johnson - October 4, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Benefit of 5ASA Use After Anti-TNF or Immunomodulator in IBD Benefit of 5ASA Use After Anti-TNF or Immunomodulator in IBD
5ASA is still used as first-line therapy in the treatment of mild to moderate ulcerative colitis. Is there a benefit to continuing it once biological or immunomodulator therapy is initiated?Alimentary Pharmacology & Therapeutics (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - September 29, 2021 Category: Surgery Tags: Gastroenterology Journal Article Source Type: news
Do you suffer with IBS? Your symptoms could be a sign of a more serious condition - expert
IRRITABLE bowel syndrome causes abdominal symptoms that include constipation, diarrhoea, or both. However, the condition does not damage a person's bowel like ulcerative colitis or Crohn's disease can. Symptoms can consist of flare ups that can cause excruciating pain and can make going about your daily life uncomfortable. For years, IBS has often been diagnosed before another, more serious condition. (Source: Daily Express - Health)
Source: Daily Express - Health - September 25, 2021 Category: Consumer Health News Source Type: news
Can Cannabis Help Your Gut?
When Joe Silverman developed Crohn’s disease at age 21, the symptoms started out mild. While the sight of blood in his stools initially freaked him out, what really bothered him was the frequent abdominal pain and bloating that occurred as his condition progressed to moderate and then severe. Dietary changes didn’t make a difference, so he began taking prescription oral anti-inflammatory drugs that are often used to treat certain bowel diseases, which alleviated but didn’t eliminate his discomfort. He started using prescription steroid suppositories to cope with flare-ups of the inflammatory bowel disease...
Source: TIME: Health - September 23, 2021 Category: Consumer Health News Authors: Stacey Colino Tags: Uncategorized Source Type: news
Statins can lower cholesterol - but a study has found another surprising health benefit
STATINS are a group of medicines that can help lower the level of cholesterol in the blood. Satins can also be taken to prevent heart disease, including heart attacks and strokes. Now, a new study has found that the cheap pills may also help treat ulcerative colitis. (Source: Daily Express - Health)
Source: Daily Express - Health - September 18, 2021 Category: Consumer Health News Source Type: news
Statin Cholesterol Drugs May Help Fight Ulcerative Colitis
Title: Statin Cholesterol Drugs May Help Fight Ulcerative ColitisCategory: Health NewsCreated: 9/16/2021 12:00:00 AMLast Editorial Review: 9/17/2021 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - September 17, 2021 Category: Nutrition Source Type: news
Statins don't just lower cholesterol! Study finds cheap pills may also help treat ulcerative colitis
Stanford University researchers have found that atrorvastatin - sold under the name Lipitor for just 54p a pill - slashes the risk of being hospitalised with the painful condition by half. (Source: the Mail online | Health)
Source: the Mail online | Health - September 16, 2021 Category: Consumer Health News Source Type: news
